Celltrion To Begin Denosumab Trials Within Days
Plans To Complete Trials Before Prolia’s Patent Expires
Celltrion has announced plans to proceed to Phase I clinical trials of its Prolia/Xgeva (denosumab) biosimilar candidate. The company is also working on biosimilar versions of bevacizumab, omalizumab and ustekinumab for both Europe and the US.
You may also be interested in...
Celltrion has kicked off plans for a Phase III trial for its denosumab biosimilar rival to Prolia.
Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.